One year outcomes of transfemoral J-valve for chronic aortic regurgitation, a prospective multicenter study in 127 cases

In this #europcr 2025 roundtable, Lai Wei and Dongming Hou present the latest data on the transfemoral J-Valve for chronic aortic regurgitation.

They begin with the China-DVD study, highlighting that aortic regurgitation is now slightly more prevalent than aortic stenosis in China. The conversation then shifts to the evolution from transapical to transfemoral access, and focuses on the one-year outcomes of the transfemoral J-Valve, based on a prospective multicenter study in 127 high-risk patients with moderate or severe AR and large annuli.

The results? Zero mortality at one year, excellent safety, and strong hemodynamic performance leading to symptom relief, improved exercise tolerance, and enhanced quality of life.

This interview was filmed at EuroPCR 2025: see more videos here.